BMS plant closure "will halt vital HIV drug to children"
This article was originally published in Scrip
Executive Summary
NGOs are concerned with plans by Bristol-Myers Squibb to close down its Meymac plant in France, saying it will affect supplies of the only prequalified second-line antiretroviral, Videx (buffered didanosine 25 mg tablets), for use in children with HIV in developing countries weighing less than 10kg.